Abstract
In a recent issue of Gynecologic Oncology, Bell et al. report the final results of a Gynecologic Oncology Group (GOG) phase III randomized trial that compared 3 cycles to 6 cycles of carboplatin plus paclitaxel as adjuvant treatment of high risk early stage epithelial ovarian carcinoma [ [1] Bell J. Brady M.F. Young R.C. et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2006; 102: 432-439 Abstract Full Text Full Text PDF PubMed Scopus (225) Google Scholar ]. The authors conclude that, “compared to 3 cycles, 6 cycles of C and P do not significantly alter the recurrence rate in high risk early stage EOC but are associated with more toxicity”.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
